Net Profit Margin: 27.86%
Is the net profit margin high or low?
The net profit margin of 27.86% is 27% above its 5-year average of 21.98%, near the high end of its 5-year range (-10.21%–28.26%).
As of Friday, June 26, 2026. 0.95% above its 12-month average of 27.59%.
RMD Profit Margin
Reported quarterly profit margin; no daily interpolation.
RMD Average Net Profit Margin Chart
RMD Current vs Average Net Profit Margin Chart
RMD Net Profit Margin Metrics
NET PROFIT MARGIN
27.86%
NET PROFIT MARGIN AVG TTM
27.59%
NET PROFIT MARGIN AVG 3Y
24.49%
NET PROFIT MARGIN AVG 5Y
23.58%
NET PROFIT MARGIN AVG 10Y
21.01%
NET PROFIT MARGIN AVG 15Y
20.92%
NET PROFIT MARGIN AVG 20Y
19.54%
CURRENT VS TTM AVG
+0.95%
CURRENT VS 3Y AVG
+13.73%
CURRENT VS 5Y AVG
+18.11%
CURRENT VS 10Y AVG
+32.61%
CURRENT VS 15Y AVG
+33.14%
CURRENT VS 20Y AVG
+42.58%
RMD Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ResMed Inc. (RMD) | $28.81B | 27.86% | 27.59% | 24.49% | 23.58% |
| DexCom, Inc. (DXCM)vs › | $26.82B | 19.31% | 16.12% | 14.73% | 15.57% |
| Moderna, Inc. (MRNA)vs › | $26.45B | -143.55% | -128.24% | -70.25% | -50.87% |
| Biogen Inc. (BIIB)vs › | $31.51B | 13.92% | 15.03% | 17.95% | 19.29% |
| IQVIA Holdings Inc. (IQV)vs › | $31.58B | 8.33% | 8.63% | 8.47% | 7.22% |
| Veeva Systems Inc. (VEEV)vs › | $25.68B | 28.37% | 27.22% | 24.83% | 24.72% |
| Medline Inc. (MDLN)vs › | $31.94B | 3.31% | 4.39% | 2.42% | 2.42% |
| Zoetis Inc. (ZTS)vs › | $32.06B | 27.79% | 27.55% | 27.17% | 26.57% |
| Centene Corp. (CNC)vs › | $32.31B | -3.43% | -0.70% | 0.29% | 0.65% |
| Mettler-Toledo International Inc. (MTD)vs › | $25.24B | 21.40% | 21.94% | 21.74% | 21.20% |
Margin Comparison
Operating Margin
34.3%
Net Profit Margin
27.9%
Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Net Profit Margin FAQ
- What is the net profit margin for ResMed Inc. (RMD)?
- The net profit margin for RMD stock is 27.86%.
- Is ResMed Inc.'s net profit margin high or low?
- The net profit margin of 27.86% is 27% above its 5-year average of 21.98%, near the high end of its 5-year range (-10.21%–28.26%).
- What is the TTM average net profit margin for ResMed Inc. (RMD)?
- The TTM average net profit margin for RMD stock is 27.59%.
- What is the 3Y average net profit margin for ResMed Inc. (RMD)?
- The 3Y average net profit margin for RMD stock is 24.49%.
- What is the 5Y average net profit margin for ResMed Inc. (RMD)?
- The 5Y average net profit margin for RMD stock is 23.58%.
- What is the 10Y average net profit margin for ResMed Inc. (RMD)?
- The 10Y average net profit margin for RMD stock is 21.01%.
- What is the 15Y average net profit margin for ResMed Inc. (RMD)?
- The 15Y average net profit margin for RMD stock is 20.92%.
- What is the 20Y average net profit margin for ResMed Inc. (RMD)?
- The 20Y average net profit margin for RMD stock is 19.54%.
RMD Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-03-31 | 27.86% |
| 2025-12-31 | 27.59% |
| 2025-09-30 | 26.10% |
| 2025-06-30 | 28.17% |
| 2025-03-31 | 28.26% |
| 2024-12-31 | 26.88% |
| 2024-09-30 | 25.43% |
| 2024-06-30 | 23.89% |
| 2024-03-31 | 25.10% |
| 2023-12-31 | 17.96% |
| 2023-09-30 | 19.91% |
| 2023-06-30 | 20.47% |
| 2023-03-31 | 20.82% |
| 2022-12-31 | 21.76% |
| 2022-09-30 | 22.15% |
| 2022-06-30 | 21.32% |
| 2022-03-31 | 20.71% |
| 2021-12-31 | 22.55% |
| 2021-09-30 | 22.52% |
| 2021-06-30 | 22.27% |
| 2021-03-31 | -10.21% |
| 2020-12-31 | 22.44% |
| 2020-09-30 | 23.72% |
| 2020-06-30 | 23.09% |
| 2020-03-31 | 21.20% |
| 2019-12-31 | 21.81% |
| 2019-09-30 | 17.64% |
| 2019-06-30 | 9.76% |
| 2019-03-31 | 15.92% |
| 2018-12-31 | 19.14% |
| 2018-09-30 | 17.97% |
| 2018-06-30 | 17.61% |
| 2018-03-31 | 18.61% |
| 2017-12-31 | 1.58% |
| 2017-09-30 | 16.45% |
| 2017-06-30 | 18.25% |
| 2017-03-31 | 17.08% |
| 2016-12-31 | 14.47% |
| 2016-09-30 | 16.35% |
| 2016-06-30 | 16.03% |
| 2016-03-31 | 20.00% |
| 2015-12-31 | 21.03% |
| 2015-09-30 | 20.14% |
| 2015-06-30 | 19.30% |
| 2015-03-31 | 21.53% |
| 2014-12-31 | 21.56% |
| 2014-09-30 | 21.89% |
| 2014-06-30 | 21.13% |
| 2014-03-31 | 22.62% |
| 2013-12-31 | 22.54% |
| 2013-09-30 | 22.63% |
| 2013-06-30 | 17.61% |
| 2013-03-31 | 22.14% |
| 2012-12-31 | 20.70% |
| 2012-09-30 | 20.98% |
| 2012-06-30 | 20.66% |
| 2012-03-31 | 18.51% |
| 2011-12-31 | 18.90% |
| 2011-09-30 | 16.05% |
| 2011-06-30 | 17.10% |
| 2011-03-31 | 17.03% |
| 2010-12-31 | 19.10% |
| 2010-09-30 | 20.11% |
| 2010-06-30 | 18.23% |
| 2010-03-31 | 17.52% |
| 2009-12-31 | 16.71% |
| 2009-09-30 | 17.05% |
| 2009-06-30 | 18.01% |
| 2009-03-31 | 17.20% |
| 2008-12-31 | 15.18% |
| 2008-09-30 | 12.86% |
| 2008-06-30 | 12.60% |
| 2008-03-31 | 14.01% |
| 2007-12-31 | 13.25% |
| 2007-09-30 | 12.99% |
| 2007-06-30 | 14.47% |
| 2007-03-31 | -8.40% |
| 2006-12-31 | 16.25% |
| 2006-09-30 | 15.28% |
| 2006-06-30 | 13.49% |
| 2006-03-31 | 16.24% |
| 2005-12-31 | 15.24% |
| 2005-09-30 | 12.93% |
| 2005-06-30 | 12.42% |
| 2005-03-31 | 16.48% |
| 2004-12-31 | 16.75% |
| 2004-09-30 | 15.87% |
| 2004-06-30 | 17.07% |
| 2004-03-31 | 16.47% |
| 2003-12-31 | 17.20% |
| 2003-09-30 | 16.81% |
| 2003-06-30 | 16.76% |
| 2003-03-31 | 17.75% |
| 2002-12-31 | 15.90% |
| 2002-09-30 | 16.34% |
| 2002-06-30 | 17.44% |
Related Metrics
About ResMed Inc.
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael J. Farrell